Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

Sponsor

Providence Health & Services (Other)

Overall Status

Terminated

CT.gov ID

NCT00232206

Collaborator

Providence Cancer Center, Earle A. Chiles Research Institute (Other), Sanofi (Industry)

Enrollment

Location

Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC). Secondary objectives of this study include assessment of radiographic response rate by computed tomography (CT) scanning, overall survival, time to progression, rate of complete surgical removal, and adverse reactions. In addition, this study will test whether positron emission tomography (PET) imaging can predict a tumor response. Patients who have a response to chemotherapy may receive 2 additional cycles after recovering from surgery.

Condition or Disease	Intervention/Treatment	Phase
Non-small-Cell Lung Carcinoma	Drug: Neoadjuvant Therapy with Cisplatin Plus Docetaxel	Phase 2

Detailed Description

Non-small cell lung cancer (NSCLC) accounts for 80% of new lung cancer diagnoses in the US. Surgery is the primary most successful treatment for early stage patients. However, even lung cancers caught at an early stage (stage IB through selected IIIA) have 5 year survivals after surgery at a rate of only 10-60%. Postoperative platinum based chemotherapy offers a 4-15% survival benefit, depending on stage in fit patients after complete surgical removal of early stage disease. Preoperative platinum based chemotherapy has been shown in small randomized trials to benefit patients with stage IIIA, N2 positive disease, but is not standard of care in earlier stage disease, such as the population in this study.

The combination of cisplatin and docetaxel is approved in the US for front line therapy of stage IV NSCLC based on randomized clinical data showing efficacy and manageable toxicity. Given the efficacy and tolerance of this combination in the metastatic setting, this regimen is an obvious choice for study in the neoadjuvant setting.

PET imaging is approved in the US for determining size, site and spread of lung cancer (staging) and has been shown to reduce unnecessary surgery when used as part of preoperative evaluation. Because NSCLC is not 100% responsive to chemotherapy and CT scans may not show a change in tumor size until after several cycles of chemotherapy, PET imaging might be an effective way to provide an earlier and more reliable estimate of response.

Preoperative chemotherapy will be given for a total of two cycles 21 days apart if any adverse events have resolved and there is no evidence of disease progression. Patients will undergo CT chest through liver and PET scans for restaging following the second cycle and will then be scheduled for surgery 3-6 weeks after the second cycle of chemotherapy. Patients who have responded according to CT and/or PET imaging, or surgical pathology will go on to receive an additional two cycles of chemotherapy with docetaxel and cisplatin once the patient has recovered from surgery.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

Non-Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase II Study of Cisplatin Plus Docetaxel as Neoadjuvant Therapy for Stages IB Through Selected IIIA NSCLC

Study Start Date :

May 1, 2005

Actual Primary Completion Date :

Apr 1, 2007

Study Completion Date :

Nov 1, 2007

Outcome Measures

Primary Outcome Measures

Primary objective: To assess the pathologic complete and partial response rate to neoadjuvant treatment with two cycles of cisplatin and docetaxel chemotherapy prior to resection of early stage NSCLC []

Secondary Outcome Measures

Secondary objectives: Assessment of radiographic response rate by CT scanning, overall survival, time to progression, rate of complete surgical resection and toxicity []
Evaluation of the predictive power of PET to define pathologic response []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed NSCLC appropriate for surgery
Medically fit for resection by lobectomy or pneumonectomy
T1-2N1 disease by CT must have negative N2/N3 nodes by PET
T3N1 disease must have pathologically negative N2/N3 nodes
Measurable disease
Patients must not be receiving other investigational therapy
Prior surgery for NSCLC okay if resected > or = 5 years prior
No prior chemotherapy or radiation for NSCLC
No uncontrolled medical problems
No factors that would preclude obtaining informed consent
Age 18 or greater
Performance status (PS) 0-1
Peripheral neuropathy must be < grade 1
Acceptable hematologic and chemistry parameters
Renal: creatinine clearance (calculated) > 50 cc/min

Exclusion Criteria:

History of severe hypersensitivity to docetaxel or like drugs
Pregnant or nursing women
Prior chemotherapy or radiation for NSCLC
Symptomatic superior sulcus tumors
Prior malignancy except for treated non-melanoma skin cancer, in situ cervical cancer, localized prostate cancer or cancer from which the patient has been disease free for greater than three years